乳腺癌COX-2、P-gp的表达与新辅助化疗的关系

Expression of COX-2,P-gp in breast cancer and its relation to neoadjuvant chemotherapy

目的:研究COX-2、P-gp在乳腺癌新辅助化疗前后的表达变化,及其与新辅助化疗疗效的关系。方法:应用免疫组织化学法检测48例乳腺癌新辅助化疗前后标本中COX-2、P-gp的表达。结果:新辅助化疗有效率为70.8%。化疗前后COX-2表达变化显著,由化疗前的62.5%降到化疗后的41.7%,P<0.05;P-gp表达无明显变化。化疗前后COX-2表达与P-gp正相关,P<0.05。新辅助化疗前COX-2、P-gp表达阳性者,化疗效果差,P<0.05。结论:COX-2、P-gp可作为指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。

Objective ：To observe the change of COX -2 and P - gp expression after neoadjuvant chemotherapy （NACT） in breast cancer and its correlation with the clinical response to NACT. Methods： COX -2 and P-gp were examined by immunohistochemical staining in 48 breast cancer samples. Results： The overall response rate to neoadjuvant chemotherapy was 70.8%. The expression of COX - 2 in post - neoadjuvant chemotherapy 41.7% was significantly lower than that in prr-neoadjuvant chemotherapy 62.5% ,P 〈0.05. P-gp expression had no significant change. COX - 2 had positive correlation with P - gp before and after NACT. The effect of NACT had signifi-cantly negative correlations with COX - 2 and P - gp expression. Conclusion ： The expression of COX - 2 and P - gp as molecular markers could be a guide for chemotherapy and prediction for its response to chemotherapy in breast cancer.